Artemis Investment Management LLP holds $13.41M position in Johnson & Johnson (NYSE:JNJ)


Artemis Investment Management LLP acquired a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating ) during the first quarter, Holdings Channel reports. The firm acquired 75,814 shares of the company’s stock, valued at approximately $13,408,000.

Several other institutional investors have also made changes to their positions in the company. Ellsworth Advisors LLC raised its position in shares of Johnson & Johnson by 1.7% in the first quarter. Ellsworth Advisors LLC now owns 9,710 shares of the company’s stock valued at $1,786,000 after acquiring an additional 162 shares during the last quarter. Berkshire Bank raised its position in shares of Johnson & Johnson by 2.2% in the first quarter. Berkshire Bank now owns 14,435 shares of the company’s stock valued at $2,558,000 after acquiring an additional 306 shares in the last quarter. Zhang Financial LLC raised its position in shares of Johnson & Johnson by 265.0% in the first quarter. Zhang Financial LLC now owns 36,771 shares of the company’s stock valued at $6,517,000 after acquiring an additional 26,697 shares during the last quarter. apricus wealth LLC raised its position in shares of Johnson & Johnson by 13.1% during the first quarter. apricus wealth LLC now owns 16,046 shares of the company’s stock valued at $2,951,000 after acquiring an additional 1,854 shares in the last quarter. Finally, Western Pacific Wealth Management LP lifted its position in shares of Johnson & Johnson by 3.0% in the first quarter. Western Pacific Wealth Management LP now owns 2,605 shares of the company’s stock valued at $461,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s shares.

In other news, insider William Haight sold 29,699 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. Disclosure of this sale can be found here. Over the last ninety days, insiders have sold 78,161 shares of company stock worth $13,895,302. Insiders own 0.35% of the company’s stock.

A number of equities analysts recently commented on the company. Citigroup cut their target price on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Raymond James upped their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Morgan Stanley boosted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $190.67, according to MarketBeat .

Shares of NYSE JNJ opened at $178.28 on Friday. The business’s 50-day moving average is $176.89, and its two-hundred-day moving average is $174.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39, and a quick ratio of 1.14. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a market cap of $469.13 billion, a P/E ratio of 24.03, a PEG ratio of 3.53 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. The firm had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. In the same quarter last year, the firm reported $2.59 earnings per share. As a group, equities research analysts expect Johnson & Johnson to post 10.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents an annualized dividend of $4.52 and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and markets a variety of health care products worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; LISTERINE brand oral care products; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating) .

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Get news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.